ARTICLE | Finance
Patience is priceless: crossovers deliver $140M series C to Versant-backed Ventus
Funding gives Ventus firepower to take three programs to IND
February 10, 2022 3:48 AM UTC
A crossover-heavy syndicate led by SoftBank and RA Capital and a fresh $140 million in venture money affords Ventus time to wait out the rocky capital markets before seeking its first public fund-raising.
When BioCentury spoke with Ventus Therapeutics Inc. President and CEO Marcelo Bigal in 2021, he said an IPO was on the cards within a year or so, but the company’s series B round could provide it runway through 2024...